Orgenesis (FRA:45O) FCF Margin % : -3,287.69% (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Orgenesis FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Orgenesis's Free Cash Flow for the three months ended in Mar. 2024 was €-4.27 Mil. Orgenesis's Revenue for the three months ended in Mar. 2024 was €0.13 Mil. Therefore, Orgenesis's FCF Margin % for the quarter that ended in Mar. 2024 was -3,287.69%.

As of today, Orgenesis's current FCF Yield % is -78.98%.

The historical rank and industry rank for Orgenesis's FCF Margin % or its related term are showing as below:

FRA:45O' s FCF Margin % Range Over the Past 10 Years
Min: -3194.91 Med: -113.85 Max: -47.66
Current: -2469.88

During the past 13 years, the highest FCF Margin % of Orgenesis was -47.66%. The lowest was -3194.91%. And the median was -113.85%.

FRA:45O's FCF Margin % is ranked worse than
83.46% of 1046 companies
in the Biotechnology industry
Industry Median: -144.01 vs FRA:45O: -2469.88

Orgenesis FCF Margin % Historical Data

The historical data trend for Orgenesis's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orgenesis FCF Margin % Chart

Orgenesis Annual Data

Trend

Nov14

Nov15

Nov16

Nov17

Nov18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-650.16

-1,039.87

-97.83

-103.65

-3,195.06

Orgenesis Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
FCF Margin %	Get a 7-Day Free Trial															-5,986.47	-5,702.88	-1,347.57	-304.64	-3,287.69

Competitive Comparison of Orgenesis's FCF Margin %

For the Biotechnology subindustry, Orgenesis's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Orgenesis's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Orgenesis's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Orgenesis's FCF Margin % falls into.

Orgenesis FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Orgenesis's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-15.528	/	0.486
	=	-3,195.06 %

Orgenesis's FCF Margin for the quarter that ended in Mar. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	-4.274	/	0.13
	=	-3,287.69 %

Orgenesis FCF Margin % Related Terms

Thank you for viewing the detailed overview of Orgenesis's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Orgenesis (FRA:45O) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orgenesis Inc (FRA:45O) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

ORGS:USA

Address

20271 Goldenrod Lane, Germantown, MD, USA, 20876

Website

https://www.orgenesis.com

Orgenesis Inc is a biotech company working to unlock the potential of cell and gene therapies. It is focused on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient for treatment of the patient at the point of care (POCare). The Company's business includes two reporting segments: Morgenesis and Therapies.

Orgenesis (FRA:45O) Headlines

No Headlines